What did the FDA advisory committee actually vote on, and does the vote change anything yet?
Eptides Wholesale Real Peptide The committee recommended six of seven nominated peptides for the Section 503A Bulks List, and the vote changes no legal status on its own. The six were BPC-157, KPV, TB-500, c-워드, Semax and Epitalon; emideltide, also called DSIP, was not recommended (the committee’s July 2026 meeting record). The meeting split across two days, with four substances heard on 23 July and three on 24 칠월, and every vote was divided (the §503A pathway analysis).
<피규어 클래스="블로그 차트" 스타일="최대 너비:640px;여유:1.5렘 자동;글꼴 크기:12px;선 높이:1.3;색상:상속하다"> <svg viewBox="0 0 560 380" 스타일="최대 너비: 100%; 키: 자동; 글꼴 모음: '인터', 시스템 UI, 산세리프체; 색상: #1e293b; --차트 음소거: #64748비;" 역할="img" aria-labelledby="pcac-vote-tallies-by-peptide-title pcac-vote-tallies-by-peptide-desc"> <스타일> /* 렌더러는 요소 배경이 검은색인 iframe에 차트를 넣습니다., iframe은 차트와 모양이 다릅니다, 그래서 레터박스 밴드 주위에 검은색 프레임으로 표시되었습니다. (찌르다 09-22). iframe 내부의 문서는 기본적으로 투명합니다.; 여기에 그림을 그리는 것은 요소 배경을 덮습니다., 대신 차트가 인라인되면 이는 아무것도 일치하지 않습니다.. 이 블록에서 꺾쇠 괄호를 사용하지 마세요.: SVG 내부의 스타일 요소는 외부 콘텐츠로 구문 분석됩니다., 그래서 하나의 길 잃은 괄호는 그 안에 있는 모든 규칙을 버립니다.. */ HTML, 몸 { 배경: #ffffff; 여유: 0; } @메디아 (선호 감소 모션: 줄이다) { * { 생기: 없음 !중요한; 이행: 없음 !중요한; } } </스타일> <직사각형 x="0" y="0" 너비="560" 키="380" RX="8" 채우기="#ffffff" /> <제목 ID="pcac-vote-tallies-by-peptide-title">PCAC vote tallies by peptide</제목> <설명 ID="pcac-vote-tallies-by-peptide-desc">PCAC vote tallies by peptide, 인용된 출처에서 플롯한 대로. PCAC vote tallies by peptide. 그룹화된 막대 데이터: BPC-157: 을 위한 8, Against 6, 기권 1; KPV: 을 위한 8, Against 6, 기권 1; TB-500: 을 위한 8, Against 6, 기권 1; c-워드: 을 위한 7, Against 5, 기권 2; 듣지 마세요: 을 위한 8, Against 5, 기권 1; 에피탈론: 을 위한 7, Against 4, 기권 1; 에미델티드: 을 위한 6, Against 7, 1. 출처를 기권한다: Bass Berry & 심즈, client alert on the PCAC vote 2026-07-31.</설명> <텍스트 x="280.0" y="29" 텍스트 앵커="가운데" 글꼴 크기="18" 글꼴 두께="800" 채우기="현재색상">PCAC vote tallies by peptide</텍스트> <라인 x1="72" y1="277.0" x2="492" y2="277.0" 뇌졸중="현재색상" 불투명도="0.08" /> <라인 x1="72" y1="230.8" x2="492" y2="230.8" 뇌졸중="현재색상" 불투명도="0.08" /> <라인 x1="72" y1="184.5" x2="492" y2="184.5" 뇌졸중="현재색상" 불투명도="0.08" /> <라인 x1="72" y1="138.2" x2="492" y2="138.2" 뇌졸중="현재색상" 불투명도="0.08" /> <라인 x1="72" y1="92.0" x2="492" y2="92.0" 뇌졸중="현재색상" 불투명도="0.08" /> <텍스트 x="66" y="281.0" 텍스트 앵커="끝" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.7">0</텍스트> <텍스트 x="66" y="234.8" 텍스트 앵커="끝" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.7">2.5</텍스트> <텍스트 x="66" y="188.5" 텍스트 앵커="끝" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.7">5</텍스트> <텍스트 x="66" y="142.2" 텍스트 앵커="끝" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.7">7.5</텍스트> <텍스트 x="66" y="96.0" 텍스트 앵커="끝" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.7">10</텍스트> <직사각형 x="72.0" y="62" 너비="10" 키="10" 채우기="#f97316" /> <텍스트 x="87.0" y="71" 글꼴 크기="11" 채우기="현재색상">을 위한</텍스트> <직사각형 x="127.6" y="62" 너비="10" 키="10" 채우기="#38bdf8" /> <텍스트 x="142.6" y="71" 글꼴 크기="11" 채우기="현재색상">Against</텍스트> <직사각형 x="208.0" y="62" 너비="10" 키="10" 채우기="#a78bfa" /> <텍스트 x="223.0" y="71" 글꼴 크기="11" 채우기="현재색상">기권</텍스트> <직사각형 x="79.0" y="129.0" 너비="13.3" 키="148.0" 채우기="#f97316" /> <텍스트 x="85.7" y="125.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">8</텍스트> <직사각형 x="94.3" y="166.0" 너비="13.3" 키="111.0" 채우기="#38bdf8" /> <텍스트 x="101.0" y="162.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">6</텍스트> <직사각형 x="109.7" y="258.5" 너비="13.3" 키="18.5" 채우기="#a78bfa" /> <텍스트 x="116.3" y="254.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">1</텍스트> <텍스트 x="102.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="102.0" 다이="0">BPC-157</tspan></텍스트> <직사각형 x="139.0" y="129.0" 너비="13.3" 키="148.0" 채우기="#f97316" /> <텍스트 x="145.7" y="125.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">8</텍스트> <직사각형 x="154.3" y="166.0" 너비="13.3" 키="111.0" 채우기="#38bdf8" /> <텍스트 x="161.0" y="162.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">6</텍스트> <직사각형 x="169.7" y="258.5" 너비="13.3" 키="18.5" 채우기="#a78bfa" /> <텍스트 x="176.3" y="254.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">1</텍스트> <텍스트 x="162.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="162.0" 다이="0">KPV</tspan></텍스트> <직사각형 x="199.0" y="129.0" 너비="13.3" 키="148.0" 채우기="#f97316" /> <텍스트 x="205.7" y="125.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">8</텍스트> <직사각형 x="214.3" y="166.0" 너비="13.3" 키="111.0" 채우기="#38bdf8" /> <텍스트 x="221.0" y="162.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">6</텍스트> <직사각형 x="229.7" y="258.5" 너비="13.3" 키="18.5" 채우기="#a78bfa" /> <텍스트 x="236.3" y="254.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">1</텍스트> <텍스트 x="222.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="222.0" 다이="0">TB-500</tspan></텍스트> <직사각형 x="259.0" y="147.5" 너비="13.3" 키="129.5" 채우기="#f97316" /> <텍스트 x="265.7" y="143.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">7</텍스트> <직사각형 x="274.3" y="184.5" 너비="13.3" 키="92.5" 채우기="#38bdf8" /> <텍스트 x="281.0" y="180.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">5</텍스트> <직사각형 x="289.7" y="240.0" 너비="13.3" 키="37.0" 채우기="#a78bfa" /> <텍스트 x="296.3" y="236.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">2</텍스트> <텍스트 x="282.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="282.0" 다이="0">c-워드</tspan></텍스트> <직사각형 x="319.0" y="129.0" 너비="13.3" 키="148.0" 채우기="#f97316" /> <텍스트 x="325.7" y="125.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">8</텍스트> <직사각형 x="334.3" y="184.5" 너비="13.3" 키="92.5" 채우기="#38bdf8" /> <텍스트 x="341.0" y="180.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">5</텍스트> <직사각형 x="349.7" y="258.5" 너비="13.3" 키="18.5" 채우기="#a78bfa" /> <텍스트 x="356.3" y="254.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">1</텍스트> <텍스트 x="342.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="342.0" 다이="0">듣지 마세요</tspan></텍스트> <직사각형 x="379.0" y="147.5" 너비="13.3" 키="129.5" 채우기="#f97316" /> <텍스트 x="385.7" y="143.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">7</텍스트> <직사각형 x="394.3" y="203.0" 너비="13.3" 키="74.0" 채우기="#38bdf8" /> <텍스트 x="401.0" y="199.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">4</텍스트> <직사각형 x="409.7" y="258.5" 너비="13.3" 키="18.5" 채우기="#a78bfa" /> <텍스트 x="416.3" y="254.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">1</텍스트> <텍스트 x="402.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="402.0" 다이="0">에피탈론</tspan></텍스트> <직사각형 x="439.0" y="166.0" 너비="13.3" 키="111.0" 채우기="#f97316" /> <텍스트 x="445.7" y="162.0" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">6</텍스트> <직사각형 x="454.3" y="147.5" 너비="13.3" 키="129.5" 채우기="#38bdf8" /> <텍스트 x="461.0" y="143.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">7</텍스트> <직사각형 x="469.7" y="258.5" 너비="13.3" 키="18.5" 채우기="#a78bfa" /> <텍스트 x="476.3" y="254.5" 텍스트 앵커="가운데" 글꼴 크기="9" 채우기="현재색상">1</텍스트> <텍스트 x="462.0" y="295.0" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="현재색상" 불투명도="0.8"><t스팬 x="462.0" 다이="0">에미델티드</tspan></텍스트> <텍스트 x="280.0" y="366" 텍스트 앵커="가운데" 글꼴 크기="10" 채우기="우리의(--차트 음소거, 현재색상)">원천: Bass Berry & 심즈, client alert on the PCAC vote (2026-07-31)</텍스트> </svg> </수치>
The tallies matter less than their shape. BPC-157, KPV and TB-500 each carried 8–6 with 1 기권; MOTS-c carried 7–5 with 2 기권; Semax 8–5 with 1 기권; Epitalon 7–4 with 1 기권. Emideltide failed with six for, seven against and one abstention (the vote-by-vote table). The margins ranged from 7–4 to 8–6, which is a committee divided by one or two seats on substances it was willing to recommend.
Nothing is on the list yet. The votes are advisory, the HHS Secretary must formally approve any addition, and pharmacies cannot compound these peptides until final rulemaking is in place, even where pharmaceutical-grade API exists (pharmacy trade coverage of the vote). The list itself is created by regulation under section 503A(기음), as the Federal Register meeting notice 밖으로 나간다, so inclusion is a rulemaking act rather than a committee act. Reading the tally as a decision is the first failure mode, and it is a reading error, not a regulatory one.
Why did FDA’s own staff scientists oppose all six peptides?
That divided recommendation rested on objections FDA staff had already put on the record. FDA staff opposed every addition on three grounds: no solid clinical trial data, inconsistent formulations from batch to batch, and the risk of harmful immune reactions (reporting from the meeting). Two of those three are chemistry problems. Batch inconsistency is a manufacturing-control problem, and immunogenicity in a peptide context is largely an impurity and aggregation problem, 그렇기 때문에 FDA’s compounding-safety material flags GHRP-2, GHRP-6, ipamorelin acetate and kisspeptin-10 for immunogenicity risk “due to the potential for aggregation and peptide-related impurities.”
The characterization record was thin in specific, checkable ways. All peptides except TB-500 were found “not well-characterized from the physical and chemical characterization perspective”; KPV’s proposed cream and gel formulations lacked the information needed to evaluate physicochemical characteristics; Epitalon had no studies evaluating insomnia by the proposed subcutaneous route; Semax research was in mice only, with no abuse-potential data. Reviewers noted particular immunogenicity risk for injectable formulations (the briefing-document review).
Identity itself was contested. FDA’s briefers noted that common names not following USAN or INN conventions can describe different active moieties, and that free base, salt and ester forms of the same moiety differ in physicochemical, toxicological and pharmacokinetic behaviour, so a name alone is not a reliable identity (the §503A pathway analysis). For BPC-157 specifically, multiple substances are marketed under the same common name with different active moieties, so “there may be no reliable basis for ensuring a given name always identifies the same chemical structure and form” (the vote-by-vote table).
Those objections are chemical, not brand-specific. A program that answers them answers them with documents, and the six domains below are the documents.
Does being on a compounding list mean a peptide is approved, 안전한, or effective?
The bulks-list review considers physical and chemical characterization, 안전, evidence of effectiveness and historical use. It is not the new-drug approval process, but clinical evidence can be highly relevant to the safety and effectiveness criteria. Listing does not establish FDA approval.
The statutory routes are narrower than the headline suggests. A compounded product needs a USP or NF monograph, or a drug substance that is a component of an FDA-approved drug, or a place on the 503A Bulks List (그만큼 Gku Peptide Federal Register meeting notice). The bulks-list standard is not drug approval: listing turns on the four criteria, not on trials demonstrating safety and efficacy (the §503A pathway analysis).
The near-term access mechanism is likely interim enforcement discretion, possibly moving peptides into Category 1 of the interim bulks policy. That does not modify the statute, does not approve any product, would not cover research-use-only products, supplements or 503B outsourcing facilities, would not bind state boards, and could be narrowed or withdrawn without notice (10월 2026 enforcement analysis). Enforcement did not pause for the vote: FDA issued five warning letters to online peptide vendors on 24 팔월 2026, finding that research-use-only labeling did not outweigh evidence of intended human use (10월 2026 enforcement analysis).
The four criteria are a usable lens for peptide CMC documentation even outside compounding, because they ask the same questions a reviewer asks of any dossier. What they do not do is substitute for the analytical record, which is where the next four sections sit.
What identity evidence does FDA expect for a peptide, and which methods count?
At least two orthogonal methods are expected, 조합은 순서를 명확하게 확인해야 합니다.. The EMA synthetic-peptide guideline recommends at least two orthogonal identification methods for the specification and release, 질량에서 가져온, 상대 보유 시간, LC-MS, LC-MS/MS, 펩타이드 매핑, 생체 활성, 아미노산 분석 또는 NMR, with the applicant responsible for showing the chosen combination confirms the sequence (the EMA synthetic-peptide guideline).
The underlying principle is older and broader. Identity tests should be highly specific and based on unique aspects of molecular structure, and more than one test, physicochemical, biological or immunochemical, may be necessary; amino acid composition is named as useful structural information for peptides and small proteins (나는 Q6B). ICH Q6B excludes synthetic peptides from its scope and defers to the chemical-substances guideline, but its identity logic is the one regulators apply.
실패 모드가 문서화되어 있습니다.. FDA’s common-deficiencies material names reliance on one conventional HPLC method and peaks identified only by relative retention time as recurring failures, and points to UHPLC-HRMS/MS for peak identity and peak purity (FDA’s list of common deficiencies). A single mass confirmation answers a different question than a specification does.
A minimum identity record carries the sequence version, the N- and C-terminus as synthesized, the modification site and chemistry, 반대이온 형태, the lot number, the method identifier, 열, gradient and detection wavelength, Peptide Info Factory 그리고 사용된 참조 표준. The counterion belongs in that list because the same peptide as free base and as acetate is not the same drug substance, and the meeting reviewed both forms for every substance.
MOL Changes describes HPLC and mass-spectrometric testing among its services. HPLC area purity plus intact mass does not, 그 자체로, establish sequence identity, site-specific modification or an orthogonal identity package. Request the methods and evidence needed for the construct and intended use.
Why is a single HPLC purity percentage not enough, and what else must be measured?
청정, 신원, content and impurity profile are four measurements, and an area-percent figure answers only part of one. Absolute purity is difficult to determine and the results are method-dependent, so purity is estimated by a combination of methods rather than a single chromatogram (ICH Q6B’s definition of purity). ICH Q6B lists purity methods separately from impurity methods, which is why one number cannot serve as the specification.
The thresholds differ by regime, and the legal weight differs with them. 합성 펩타이드의 경우, Ph. 유로. general monograph on substances for pharmaceutical use sets peptide-related impurities to be reported above 0.1%, 위에서 확인된 0.5% 그리고 위에 자격을 갖춘 1.0%, and the EMA guideline applies the same thresholds to finished products (the EMA synthetic-peptide guideline). 나는 Q3A(R2) sets different values for drug-substance impurities at a maximum daily dose of 2 g/일 이하: 보고 0.05%, 신분증 0.10% 또는 1.0 mg/day whichever is lower, 자격 0.15% 또는 1.0 mg/일 (나는 Q3A(R2) reporting and qualification thresholds). The EMA guideline states that synthetic peptides are excluded from ICH Q3A and that its limits do not apply, so the two ladders are not interchangeable.
FDA’s draft product-specific guidance for semaglutide, revised in July 2026, uses the 0.1% 그리고 0.5% report and identify figures but adds a relative criterion: each shared impurity should not exceed the reference listed drug level or 1.0%, whichever is greater, new impurities should be reduced below 1.0%, and total active-ingredient-related impurities should not exceed the reference product (7월 2026 draft product-specific guidance). The document is marked draft and not for implementation, and it is product-specific, so it does not set a general peptide limit.
EU peptide guidance and a US semaglutide product-specific draft have different scopes. Evaluate the actual product and impurity criteria; a reporting or qualification threshold is not itself a release limit, and the semaglutide comparison cannot define US acceptance of every peptide.
How do you prove lot-to-lot reproducibility and a stability-indicating method?
Reproducibility is shown by a connected lot record and a method proven to detect degradation, not by three certificates that each report a high percentage. The EMA guideline requires that stability-indicating properties and mass balance of the method be studied, and treats timely availability of stability-indicating methods with good peak resolution and good mass balance as a prerequisite (the EMA synthetic-peptide guideline). Forced degradation studies must show both the degradation of the peptide and the ability of the analytical procedure to detect it.
Peptides make that requirement concrete. The same guideline notes that peptides tend to be thermally labile, so degradation should be detected at inappropriate storage conditions, and it lists oxidation of Cys and Met residues, 탈아미드화, hydrolysis and beta-Asp-containing sequences as degradation pathways to discuss (the EMA synthetic-peptide guideline). Formation of high-molecular-weight impurities should be investigated during stability where applicable. 펩타이드 P 팩토리
Validation has its own gate. A quantitative impurity procedure requires specificity, a range with a lower limit at the quantitation limit, 정확성과 정밀성, and a validation protocol stating intended purpose, characteristics and criteria must exist before the study (나는 Q2(R2) 테이블 1). The EMA guideline adds no additional validation requirements beyond those for other chemical active substances.
For an investigational program, the stability expectation is phase-appropriate rather than final. Stability data are required in all phases to show the substance stays within acceptable chemical and physical limits for the planned duration, and where very short-term tests are proposed the supporting data can be correspondingly limited (21 CFR 312.23).
A connected lot record looks like this: 로트 번호, the chromatogram with method identifier and reference standard, the forced-degradation result that shows the method resolves the degradants, and the stability protocol with its storage condition and timepoints. Scale-up is where the record usually breaks, because a changed impurity profile observed in pilot or commercial batches has to be compared against earlier data and its impact on quality and on the clinical and preclinical data discussed (the EMA synthetic-peptide guideline).
What clinical pharmacology and clinical documentation does a peptide need before a pre-IND conversation?
The clinical record is the weakest gate and the one that sets the timeline, because the analytical package can be rebuilt faster than human data can be generated. FDA’s own reviewers found no completed phase 3 randomized trials across all six recommended peptides, and reviewed five small human trials for BPC-157 (the committee-composition report). Valor Peptide
The per-peptide tally is thinner than the vote suggests. 보다 적음 36 human subjects across 3 studies support BPC-157, comprising a 16-subject knee injection study, a 12-patient bladder injection study and a 2-subject infusion study, with all other BPC-157 evidence animal; KPV, MOTS-c and TB-500 had a complete lack of studies in humans by any route; Semax data are limited to inadequate studies conducted abroad and not under an IND; Epitalon human trials ran in Russia and Ukraine outside FDA oversight or ICH-harmonized good clinical practice (a docket comment that tallies the human data).
The pharmacology expectations are peptide-specific and still in draft. FDA’s draft guidance on clinical pharmacology for peptide drug products, 12월 발행 2023 and marked not for implementation, treats hepatic impairment, drug-drug interactions, QTc prolongation risk and immunogenicity risk as the peptide-specific considerations (FDA’s draft peptide clinical pharmacology guidance). Industry’s comments to the docket argue that pharmacokinetic drug-drug interaction risk with peptides is low, that peptides are typically not CYP-metabolized, and that a single biomarker may not suffice, with two or more supporting better understanding of safety and efficacy (industry’s comments to the docket). Those are sponsor-side positions, not agency requirements.
The procedural route exists. A pre-IND meeting is a recognized Type B meeting category under FDA’s formal-meetings framework for PDUFA products (FDA’s PDUFA formal-meetings guidance). What the regulations do not do is set peptide-specific content: 21 CFR 312.23 requires acceptable limits and analytical methods for identity, 힘, 품질과 순도, and states that final specifications are not expected until the end of the investigational process (21 CFR 312.23). 이 글은 규제 관련 조언이 아닙니다.; a program should confirm its own package against current guidance and with FDA directly.
How do the six domains combine into one readiness decision?
The six domains form a sequence of gates, and the weakest gate sets the timeline rather than the average. Gate one is identity: at least two orthogonal methods whose combination confirms the sequence (the EMA synthetic-peptide guideline). Gate two is purity plus mass balance, with a stability-indicating method whose degradation products are actually detected. Gate three is the impurity profile taken to the applicable threshold, with co-eluting peaks resolved or the merged peak qualified.
Assess batch history with a justified sampling and comparison plan. 2분기(R2) addresses analytical-procedure validation; it is not itself a process-validation or lot-count standard.
Monitor official FDA notices for any further peptide advisory meeting and its agenda. A forecast meeting window is not a completed review or a guaranteed policy date.
자주 묻는 질문
7월은 그랬나 2026 vote add these peptides to the 503A Bulks List?
아니요. The committee recommended six of seven, and the recommendation is advisory. A substance reaches the list only through notice-and-comment rulemaking under section 503A(기음), and until a final rule issues, compounding these peptides remains outside the 503A safe harbour (the Federal Register meeting notice).
는 98% HPLC purity result enough for a peptide specification?
아니요. Purity is method-dependent and estimated by a combination of methods, and ICH Q6B lists purity methods separately from impurity methods (ICH Q6B’s definition of purity). A specification also needs identity by at least two orthogonal methods, an impurity profile to the applicable threshold, content on a counterion-free anhydrous basis, and a stability-indicating method.
Which impurity thresholds apply to a synthetic peptide?
It depends on the regime. The Ph. 유로. thresholds restated in the EMA guideline are report above 0.1%, 위에서 식별 0.5% 그리고 위의 자격을 갖추세요 1.0% (the EMA synthetic-peptide guideline). 나는 Q3A(R2) 세트 0.05%, 0.10% 그리고 0.15% 일일 최대 복용량 2 g/일 이하, and the EMA guideline states those limits do not apply to synthetic peptides (나는 Q3A(R2) reporting and qualification thresholds).
What human data existed for the six recommended peptides?
FDA reviewers found no completed phase 3 randomized trials across the six (the committee-composition report). A docket comment tallies fewer than 36 subjects across 3 BPC-157 studies, no human administration studies for KPV, MOTS-c or TB-500, and foreign studies for Semax and Epitalon conducted outside an IND or ICH-harmonized good clinical practice (a docket comment that tallies the human data).
결론
The vote was a divided recommendation on four statutory criteria, and the objections behind the division were chemical and documentary: identity that a name cannot guarantee, impurity profiles that a single chromatogram cannot establish, batch inconsistency, and a clinical record that in most cases does not exist. The six-domain check turns those objections into a work list, and the weakest gate, usually clinical documentation, sets the timeline.
The next step is to run the six gates against one sequence and record where the evidence stops. A program that can state its identity methods, its impurity thresholds and their legal weight, its forced-degradation result, its lot history and its human data position has the package FDA staff said was missing, and it has it before the second batch of nominations reaches the committee.
게시자 공개: MOL Changes는 펩타이드 서비스를 공급하며 이 주제에 상업적인 관심을 갖고 있습니다.. 서비스 범위 및 기능 설명은 공급업체의 주장입니다.; 특정 구성에 대한 가용성 및 성능에는 프로젝트별 증거가 필요합니다..
